Valuation : Celltrion, Inc.

Market Cap 45,144B 33.52B 28.84B 27.14B 24.79B 46.38B 3,165B 46.5B 321B 124B 1,624B 126B 123B 5,231B P/E 2026 *
28.5x
P/E 2027 * 24.6x
Enterprise Value 47.33B 35.15M 30.24M 28.46M 25.99M 48.63M 3.32B 48.76M 336M 130M 1.7B 132M 129M 5.48B EV / Sales 2026 *
8.61x
EV / Sales 2027 * 7.37x
Free-Float
60.59%
Yield 2026 *
0.4%
Yield 2027 * 0.44%
Manager TitleAgeSince
Chief Executive Officer 65 2015-03-19
Chief Executive Officer 42 2021-03-25
President 51 2026-02-12
Director TitleAgeSince
Chairman 68 -
Director/Board Member 61 2005-03-31
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.54%-2.84%-1.90%+14.52% 50.35B
-0.40%+1.03%+439.20%+499.20% 45.2B
-1.42%+2.30%+45.46%+19.36% 44.71B
-1.22%-2.31%+12.40%+71.48% 41.24B
+0.53%-1.67%+15.16%+49.88% 33.08B
-0.21%+9.14% - - 17.81B
-0.35%-1.56%+22.59%+116.19% 16.56B
-1.01%+0.50%+15.83%+27.98% 14.82B
-1.65%-1.03%+77.75%+37.63% 14B
Average -0.92%+0.01%+78.31%+104.53% 30.86B
Weighted average by Cap. -1.04%-0.46%+94.24%+121.65%

Financials

2026 *2027 *
Net sales 5,497B 4.08B 3.51B 3.3B 3.02B 5.65B 385B 5.66B 39.05B 15.15B 198B 15.33B 14.99B 637B 6,317B 4.69B 4.04B 3.8B 3.47B 6.49B 443B 6.51B 44.88B 17.41B 227B 17.61B 17.23B 732B
Net income 1,524B 1.13B 974M 916M 837M 1.57B 107B 1.57B 10.83B 4.2B 54.82B 4.25B 4.16B 177B 1,772B 1.32B 1.13B 1.07B 973M 1.82B 124B 1.83B 12.59B 4.88B 63.73B 4.94B 4.83B 205B
Net Debt 2,190B 1.63B 1.4B 1.32B 1.2B 2.25B 154B 2.26B 15.56B 6.04B 78.78B 6.11B 5.97B 254B 1,393B 1.03B 890M 837M 765M 1.43B 97.66B 1.43B 9.9B 3.84B 50.11B 3.88B 3.8B 161B
Logo Celltrion, Inc.
Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
A